Literature DB >> 34762773

Correlation between aryl hydrocarbon receptor and IL-17+ and Foxp3+ T-cell infiltration in bladder cancer.

Soheila Fattahi1, Monireh Karimi1, Mahdi Ghatreh-Samani1, Fatemeh Taheri2, Hedayatollah Shirzad1, Faramarz Mohammad Alibeigi3, Maryam Anjomshoa4, Nader Bagheri1.   

Abstract

Bladder cancer (BC) is one of the most prevalent cancers around the world and, if not treated well, has high morbidity and mortality. Many studies have indicated that there may be various roles for the aryl hydrocarbon receptor (AHR) in the immune system. The aim of this study was to determine the frequency of Foxp3+ regulatory T (Treg) and T helper 17 cells (Th17) in BC tissue in comparison with controls and determine the relationship between AHR, Foxp3+ Treg and Th17 cells in BC. A total of 40 patients with BC were enrolled in this study. The control group was selected from non-tumoural parts of bladder tissues from the patients who have undergone cystoscopy. The percentage of regulatory T cells (Foxp3+ /CD4+ ) and Th17 (IL-17+ /CD4+ ), as well as AHR+ cells in BC tissues and controls, were determined by immunohistochemistry. The results of this study showed that the number of Foxp3+ Treg and Th17 is significantly higher in bladder tumour tissues in comparison with non-tumoural tissues. Also, the percentage of AHR+ lymphocytes and AHR+ cells was increased significantly in bladder tumour tissues rather than non-tumoural tissues. This study also found a relation between AHR and Foxp3+ /CD4+ T lymphocytes ratio cells in BC. The percentage of Foxp3+ Tregs and AHR+ cells were significantly correlated with the grade and stage of BC. An increase in the percentage of Foxp3+ Treg and Th17 cells may play an important role in tumour immunity; and determining the relationship between AHR and differentiation of Th17/Foxp3+ Treg in BC can lead to a potential cancer therapeutic possibility.
© 2021 Company of the International Journal of Experimental Pathology (CIJEP).

Entities:  

Keywords:  Foxp3+ regulatory T; T helper 17; aryl hydrocarbon receptor; bladder cancer

Mesh:

Substances:

Year:  2021        PMID: 34762773      PMCID: PMC8626624          DOI: 10.1111/iep.12392

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  33 in total

1.  Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.

Authors:  L J Chi; H T Lu; G L Li; X M Wang; Y Su; W H Xu; B Z Shen
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.

Authors:  Tao Wang; Quan Zhou; Han Zeng; Hongyu Zhang; Zhaopei Liu; Jialiang Shao; Zewei Wang; Ying Xiong; Jiajun Wang; Qi Bai; Yu Xia; Yiwei Wang; Li Liu; Yu Zhu; Le Xu; Bo Dai; Jianming Guo; Yuan Chang; Xiang Wang; Jiejie Xu
Journal:  Cancer Immunol Immunother       Date:  2020-05-04       Impact factor: 6.968

Review 4.  Th17 and regulatory T cell balance in autoimmune and inflammatory diseases.

Authors:  Mélissa Noack; Pierre Miossec
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

5.  CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer.

Authors:  Shingo Maeda; Kohei Murakami; Akiko Inoue; Tomohiro Yonezawa; Naoaki Matsuki
Journal:  Cancer Immunol Res       Date:  2019-06-03       Impact factor: 11.151

6.  Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.

Authors:  Anu Sharma; Sumit K Subudhi; Jorge Blando; Jorge Scutti; Luis Vence; Jennifer Wargo; James P Allison; Antoni Ribas; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2018-07-27       Impact factor: 12.531

7.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.

Authors:  Fumiko Ichihara; Koji Kono; Akihiro Takahashi; Hiromichi Kawaida; Hidemitsu Sugai; Hideki Fujii
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

8.  The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins.

Authors:  Marc Veldhoen; Keiji Hirota; Astrid M Westendorf; Jan Buer; Laure Dumoutier; Jean-Christophe Renauld; Brigitta Stockinger
Journal:  Nature       Date:  2008-03-23       Impact factor: 49.962

9.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

Authors:  Ilona Kryczek; Mousumi Banerjee; Pui Cheng; Linhua Vatan; Wojciech Szeliga; Shuang Wei; Emina Huang; Emily Finlayson; Diane Simeone; Theodore H Welling; Alfred Chang; George Coukos; Rebecca Liu; Weiping Zou
Journal:  Blood       Date:  2009-05-21       Impact factor: 22.113

Review 10.  AHR Function in Lymphocytes: Emerging Concepts.

Authors:  Liang Zhou
Journal:  Trends Immunol       Date:  2015-12-11       Impact factor: 16.687

View more
  2 in total

1.  Correlation between aryl hydrocarbon receptor and IL-17+ and Foxp3+ T-cell infiltration in bladder cancer.

Authors:  Soheila Fattahi; Monireh Karimi; Mahdi Ghatreh-Samani; Fatemeh Taheri; Hedayatollah Shirzad; Faramarz Mohammad Alibeigi; Maryam Anjomshoa; Nader Bagheri
Journal:  Int J Exp Pathol       Date:  2021-11-11       Impact factor: 1.925

Review 2.  Interleukin-17 Family Cytokines in Metabolic Disorders and Cancer.

Authors:  Eileen Victoria Meehan; Kepeng Wang
Journal:  Genes (Basel)       Date:  2022-09-13       Impact factor: 4.141

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.